Plasma mitochondrial DNA is associated with extrapulmonary sarcoidosis.

Sarcoidosis is an unpredictable granulomatous disease in which African Americans disproportionately experience aggressive phenotypes. Mitochondrial DNA (mtDNA) released by cells in response to various stressors contributes to tissue remodelling and inflammation. While extracellular mtDNA has emerged as a biomarker in multiple diseases, its relevance to sarcoidosis remains unknown. We aimed to define an association between extracellular mtDNA and clinical features of sarcoidosis.Extracellular mtDNA concentrations were measured using quantitative PCR for the human MT-ATP6 gene in bronchoalveolar (BAL) and plasma samples from healthy controls and patients with sarcoidosis from The Yale Lung Repository; associations between MT-ATP6 concentrations and Scadding stage, extrapulmonary disease and demographics were sought. Results were validated in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis cohort.Relative to controls, MT-ATP6 concentrations in sarcoidosis subjects were robustly elevated in the BAL fluid and plasma, particularly in the plasma of patients with extrapulmonary disease. Relative to Caucasians, African Americans displayed excessive MT-ATP6 concentrations in the BAL fluid and plasma, for which the latter compartment correlated with significantly higher odds of extrapulmonary disease.Enrichments in extracellular mtDNA in sarcoidosis are associated with extrapulmonary disease and African American descent. Further study into the mechanistic basis of these clinical findings may lead to novel pathophysiologic and therapeutic insights.

Use of proteomic analysis of endometriosis to identify different protein expression in patients with endometriosis versus normal controls.

OBJECTIVE: To use proteomic techniques, including two-dimensional electrophoresis (2-DE), Western blot, and mass spectrometry, to screen and identify proteins that were expressed differently in patients with endometriosis versus normal controls. DESIGN: First, we aimed to find a difference in the way serum and eutopic endometrial proteins were expressed in women with and without endometriosis. Second, we were interested in searching for endometriotic proteins, which were specifically recognized by sera from patients with endometriosis. SETTING: Collaborative investigation in an academic research environment. PATIENT(S): Consenting women of reproductive age taking no medications and with laparoscopically proven endometriosis. INTERVENTION(S): Surgical excision of eutopic and ectopic endometrial biopsy and phlebotomization of patients with endometriosis and controls. MAIN OUTCOME MEASURE(S): Protein expression. RESULT(S): Thirteen protein spots from serum correlated with 11 known proteins and 11 protein spots from endometrium correlated with 11 known proteins were found differently expressed between women with and without endometriosis. Some proteins may be cytoskeletons, and some may be involved in the regulation of cell cycle, signal transduction, or immunological function. Three proteins, which were identified as vimentin, beta-actin, and ATP synthase beta subunit, hybridized significantly differently between endometriosis sera and normal sera. CONCLUSION(S): The data help to establish a human endometriosis proteome database and broaden our understanding of the pathogenesis of endometriosis. Further study of the proteins identified herein will assist in the eventual development of new diagnoses and treatments for endometriosis.

Tumor necrosis factor alpha as an endogenous stimulator for circulating coupling factor 6.

OBJECTIVE: We recently showed that mitochondrial coupling factor 6 (CF6) is present as a pressor substance and a prostacyclin inhibitor in systemic circulation. However, the regulation mechanism for circulating CF6 is unknown. We investigated the role of tumor necrosis factor-alpha (TNF-alpha) in the generation and release of CF6. METHODS AND RESULTS: We used two kinds of cells, human umbilical vein endothelial cells (HUVEC) and ECV-304. The concentration of CF6 in the medium increased with time in both ECV-304 and HUVEC. Treatment of ECV-304 and HUVEC with TNF-alpha enhanced the release of CF6 in a dose-dependent manner concomitantly with the decrease in CF6 content in the mitochondria at 24 h. The released CF6 was characterized to be an active full-length peptide by Western blot. The ratio of CF6 to GAPDH mRNA, measured by real-time polymerase chain reaction, was 1.7 fold increased at 1 h after exposure to TNF-alpha in ECV-304 and HUVEC. This enhanced gene expression and release was blocked or suppressed by 70% by stable transfection of dominant negative mutant I kappa B kinase alpha whose efficacy was confirmed by blockade of translocation of NF-kappa B p65 protein and of degradation of I kappa B alpha protein. Flow cytometry analysis revealed that the cell surface-associated CF6 was significantly increased at 24 h after TNF-alpha in a dose-dependent manner. CONCLUSIONS: TNF-alpha stimulates the gene expression of CF6 via activation of NF-kappa B signaling pathway, and promotes the release of CF6 from ECV-304 and HUVEC.